Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2174730 | 0.82 | CA1 (0.40) | LCKCA1CA2PI4KB | |
| SCHEMBL4294136 | 0.81 | ALDH1A1 (0.42) | PI4KBTSHR | |
| SCHEMBL1743735 | 0.81 | ALDH1A1 (0.39) | TSHR | |
| SCHEMBL150084 | 0.79 | LCK (0.58) | LCKCA1CA2PI4KB | |
| SCHEMBL4876702 | 0.78 | MAPT (0.49) | LCKTSHR | |
| SCHEMBL1742407 | 0.78 | LCK (0.46) | LCKCA1CA2PI4KB | |
| SCHEMBL9225190 | 0.76 | LCK (0.49) | LCKCA1CA2PI4KB | |
| SCHEMBL4294152 | 0.76 | CA1 (0.36) | LCKCA1CA2PI4KBTSHR | |
| SCHEMBL24434724 | 0.76 | NPC1 (0.55) | LCKCA1CA2PI4KB | |
| SCHEMBL24675957 | 0.75 | LCK (0.46) | LCKCA1CA2PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387570-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010083246-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263647-A1 | FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE | TFEB, PCK2, JAK2 | LCK 253/4885CA1 3816/4885CA2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.